{"id":38750,"date":"2025-08-07T11:50:17","date_gmt":"2025-08-07T03:50:17","guid":{"rendered":"https:\/\/flcube.com\/?p=38750"},"modified":"2025-08-07T11:50:18","modified_gmt":"2025-08-07T03:50:18","slug":"novartis-evaluates-acquisition-of-avidity-biosciences-to-strengthen-rare-disease-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38750","title":{"rendered":"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline"},"content":{"rendered":"\n

According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS<\/a>) is evaluating a potential acquisition of Avidity Biosciences Inc. (NASDAQ: RNA<\/a>). Avidity, a biotechnology company focused on developing therapies for rare genetic disorders, currently has a market capitalization of approximately $5.8 billion. Following the news, Avidity’s stock surged 26% on the day, while shares of its competitor Dyne Therapeutics Inc. (NASDAQ: DYN<\/a>) rose by 7.5%.<\/p>\n\n\n\n

Early-Stage Discussions<\/strong>
The discussions are reportedly at an early stage and remain uncertain, with both Novartis and Avidity declining to comment. Avidity is said to be working with advisers to assess strategic options.<\/p>\n\n\n\n

Avidity’s Clinical Pipeline<\/strong>
Avidity currently has three clinical-stage drug candidates targeting various forms of muscular dystrophy, with potential approvals as early as 2027. Its lead candidate, del-zota, is being developed for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 44 skipping. The drug has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and is currently in a Phase II trial.<\/p>\n\n\n\n

Novartis’s Acquisition Strategy<\/strong>
This potential transaction aligns with Novartis’s 2025 acquisition strategy aimed at bolstering its rare disease pipeline and mitigating revenue risks posed by upcoming patent expirations of key products such as Entresto, Xolair, and Cosentyx. Earlier this year, Novartis acquired Anthos Therapeutics for $3.1 billion, reached a deal of up to $1.7 billion with Regulus Therapeutics, and signed a collaboration agreement worth up to $1 billion with Matchpoint Therapeutics.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS)…<\/p>\n","protected":false},"author":1,"featured_media":38754,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1815,4270,4271,1814,140,865,24],"class_list":["post-38750","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-avidity-biosciences","tag-dyne-therapeutics","tag-nasdaq-dyn","tag-nasdaq-rna","tag-novartis","tag-nyse-nvs","tag-rare-orphan-disease-drugs"],"yoast_head":"\nNovartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS) is evaluating a potential acquisition of Avidity Biosciences Inc. (NASDAQ: RNA). Avidity, a biotechnology company focused on developing therapies for rare genetic disorders, currently has a market capitalization of approximately $5.8 billion. Following the news, Avidity's stock surged 26% on the day, while shares of its competitor Dyne Therapeutics Inc. (NASDAQ: DYN) rose by 7.5%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38750\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline\" \/>\n<meta property=\"og:description\" content=\"According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS) is evaluating a potential acquisition of Avidity Biosciences Inc. (NASDAQ: RNA). Avidity, a biotechnology company focused on developing therapies for rare genetic disorders, currently has a market capitalization of approximately $5.8 billion. Following the news, Avidity's stock surged 26% on the day, while shares of its competitor Dyne Therapeutics Inc. (NASDAQ: DYN) rose by 7.5%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38750\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T03:50:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-07T03:50:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline\",\"datePublished\":\"2025-08-07T03:50:17+00:00\",\"dateModified\":\"2025-08-07T03:50:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750\"},\"wordCount\":251,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0703.webp\",\"keywords\":[\"Avidity Biosciences\",\"Dyne Therapeutics\",\"NASDAQ: DYN\",\"NASDAQ: RNA\",\"Novartis\",\"NYSE: NVS\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38750#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38750\",\"name\":\"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0703.webp\",\"datePublished\":\"2025-08-07T03:50:17+00:00\",\"dateModified\":\"2025-08-07T03:50:18+00:00\",\"description\":\"According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS) is evaluating a potential acquisition of Avidity Biosciences Inc. (NASDAQ: RNA). Avidity, a biotechnology company focused on developing therapies for rare genetic disorders, currently has a market capitalization of approximately $5.8 billion. Following the news, Avidity's stock surged 26% on the day, while shares of its competitor Dyne Therapeutics Inc. (NASDAQ: DYN) rose by 7.5%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38750\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38750#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline - Insight, China's Pharmaceutical Industry","description":"According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS) is evaluating a potential acquisition of Avidity Biosciences Inc. (NASDAQ: RNA). Avidity, a biotechnology company focused on developing therapies for rare genetic disorders, currently has a market capitalization of approximately $5.8 billion. Following the news, Avidity's stock surged 26% on the day, while shares of its competitor Dyne Therapeutics Inc. (NASDAQ: DYN) rose by 7.5%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38750","og_locale":"en_US","og_type":"article","og_title":"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline","og_description":"According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS) is evaluating a potential acquisition of Avidity Biosciences Inc. (NASDAQ: RNA). Avidity, a biotechnology company focused on developing therapies for rare genetic disorders, currently has a market capitalization of approximately $5.8 billion. Following the news, Avidity's stock surged 26% on the day, while shares of its competitor Dyne Therapeutics Inc. (NASDAQ: DYN) rose by 7.5%.","og_url":"https:\/\/flcube.com\/?p=38750","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-07T03:50:17+00:00","article_modified_time":"2025-08-07T03:50:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38750#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38750"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline","datePublished":"2025-08-07T03:50:17+00:00","dateModified":"2025-08-07T03:50:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38750"},"wordCount":251,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38750#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0703.webp","keywords":["Avidity Biosciences","Dyne Therapeutics","NASDAQ: DYN","NASDAQ: RNA","Novartis","NYSE: NVS","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38750#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38750","url":"https:\/\/flcube.com\/?p=38750","name":"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38750#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38750#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0703.webp","datePublished":"2025-08-07T03:50:17+00:00","dateModified":"2025-08-07T03:50:18+00:00","description":"According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS) is evaluating a potential acquisition of Avidity Biosciences Inc. (NASDAQ: RNA). Avidity, a biotechnology company focused on developing therapies for rare genetic disorders, currently has a market capitalization of approximately $5.8 billion. Following the news, Avidity's stock surged 26% on the day, while shares of its competitor Dyne Therapeutics Inc. (NASDAQ: DYN) rose by 7.5%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38750#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38750"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38750#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0703.webp","width":1080,"height":608,"caption":"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38750#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38750"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38750\/revisions"}],"predecessor-version":[{"id":38755,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38750\/revisions\/38755"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38754"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}